We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A trade group representing combination drug products is urging the FDA to draw bright lines among the agency’s centers as it considers voluntary quality standards. Read More
The FDA will consider granting orphan status for different gene therapies—even ones in the same class as a previously designated orphan treatment—based on how the therapy is delivered, a high-ranking CBER official said Friday at the Food and Drug Law Institute’s annual meeting in Washington, D.C. Read More
There is “little appetite on the part of donors to establish new global funding instruments specifically to address antimicrobial resistance,” the WHO says. Read More